Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma.

Abstract	We investigated antimicrobial drug resistance in ocular Chlamydia trachomatis 18 months after 4 biannual communitywide distributions of antimicrobial drugs in a region of Ethiopia where ocular strains of C. trachomatis are highly endemic. We found no significant differences in susceptibilities to azithromycin and doxycycline in 6 posttreatment and 4 pretreatment samples.
Authors	Kevin Cyrus Hong, Julius Schachter, Jeanne Moncada, Zhaoxia Zhou, Jenafir House, Thomas M Lietman
Journal	Emerging infectious diseases (Emerg Infect Dis) Vol. 15 Issue 7 Pg. 1088-90 (Jul 2009) ISSN: 1080-6059 [Electronic] United States
PMID	19624926 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References	Anti-Bacterial Agents Azithromycin Cycloheximide
Topics	Administration, Topical Adult Anti-Bacterial Agents (therapeutic use) Azithromycin (therapeutic use) Child Child, Preschool Chlamydia trachomatis (drug effects, genetics) Cycloheximide (pharmacology) Drug Resistance, Microbial (genetics) Ethiopia (epidemiology) Eye Diseases (drug therapy, epidemiology, microbiology) Female Genetic Predisposition to Disease Humans Infant Male Pregnancy Pregnancy Complications, Infectious (drug therapy) Prevalence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!